secwatch.observer — SEC 8-K summary
======================================

Issuer:     Maze Therapeutics, Inc. (MAZE)
CIK:        0001842295
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269624
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maze Q3 net loss $30.1M; cash $383.9M; MZE782 Phase 1 positive; Phase 2 start 2026
--------------------------------------------------------------------------------

- Net loss of $30.1M for Q3 2025 vs $24.8M loss in Q3 2024; zero license revenue.
- Cash, equivalents and marketable securities $383.9M as of Sep 30, 2025; runway into 2028 after $150M private placement.
- MZE782 Phase 1 positive: well-tolerated, dose-dependent urinary Phe and glutamine increase; eGFR dip observed.
- MZE782 Phase 2 trials in PKU and CKD expected to initiate in 2026; MZE829 HORIZON topline data by Q1 2026.
- Appointed Hervé Hoppenot as chairman and Misbah Tahir as CFO in Sep/Oct 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842295/000119312525269624/0001193125-25-269624-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842295/000119312525269624/maze-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269624

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer